The evaluation of Clostridium difficile infection (CDI) in a community hospital

Journal of Infection and Public Health

Volumn 8, Issue 2, 2015, Pages 155-160

  Daniel, Aju ^a   Rapose, Alwyn ^b,c  

^a SAINT VINCENT HOSPITAL   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

^c Reliant Medical Group Inc   (United States)

Author keywords

Antibiotics; Clostridium difficile; Diarrhea

Indexed keywords

BETA LACTAM ANTIBIOTIC; CEFALEXIN; CEFAZOLIN; CEFPODOXIME; CEFTRIAXONE; CLINDAMYCIN; LINEZOLID; MACROLIDE; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFONAMIDE; VANCOMYCIN; ANTIINFECTIVE AGENT; METRONIDAZOLE;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM DETECTION; CHRONIC KIDNEY DISEASE; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY HOSPITAL; COMORBIDITY; DIABETES MELLITUS; FECES ANALYSIS; FEMALE; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VERY ELDERLY; AGE; CLOSTRIDIUM INFECTIONS; DIARRHEA; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; PEPTOCLOSTRIDIUM DIFFICILE; SURVIVAL;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DIARRHEA; FEMALE; HOSPITALS, COMMUNITY; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84933680065     PISSN: 18760341     EISSN: 1876035X     Source Type: Journal    
DOI: 10.1016/j.jiph.2014.08.002     Document Type: Article

References (24)

1. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. Am J Gastroenterol 1997, 92:739-750.
2. Curry S.R., Muto C.A., Schlackman J.L., Pasculle A.W., Shutt K.A., Marsh J.W., et al. Use of multilocus variable number of tandem repeats analysis genotyping to determine the role of asymptomatic carriers in Clostridium difficile transmission. Clin Infect Dis 2013, 57:1094-1102.
3. O'Brien J.A., Lahue B.J., Caro J.J., Davidson D.M. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol 2007, 28(11):1219-1227.
4. Deshpande A., Pasupuleti V., Thota P., Pant C., Rolston D.D., Sferra T.J., et al. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother 2013, 68(9):1951-1961.
5. Pépin J., Saheb N., Coulombe M.A., Alary M.E., Corriveau M.P., Authier S., et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005, 41(9):1254-1260.
6. Muto C.A., Pokrywka M., Shutt K., Mendelsohn A.B., Nouri K., Posey K., et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005, 26:273-280.
7. Gopal Rao G., Mahankali Rao C.S., Starke I. Clostridium difficile-associated diarrhoea in patients with community-acquired lower respiratory infection being treated with levofloxacin compared with beta-lactam-based therapy. J Antimicrob Chemother 2003, 51(3):697-701.
8. Palmore T.N., Sohn S., Malak S.F., Eagan J., Sepkowitz K.A. Risk factors for acquisition of Clostridium difficile-associated diarrhea among outpatients at a cancer hospital. Infect Control Hosp Epidemiol 2005, 26(8):680-684.
9. Manabe Y.C., Vinetz J.M., Moore R.D., Merz C., Charache P., Bartlett J.G. Clostridium difficile colitis: an efficient clinical approach to diagnosis. Ann Intern Med 1995, 123(11):835-840.
10. Cardona D.M., Rand K.H. Evaluation of repeat Clostridium difficile enzyme immunoassay testing. J Clin Microbiol 2008, 46(11):3686-3689.
11. Cohen S.H., Gerding D.N., Johnson S., Kelly C.P., Loo V.G., McDonald L.C., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010, 31(5):431-455.
12. Savola K.L., Baron E.J., Tompkins L.S., Passaro D.J. Fecal leukocyte stain has diagnostic value for outpatients but not inpatients. J Clin Microbiol 2001, 39(1):266-269.
13. Reddymasu S., Sheth A., Banks D.E. Is Fecal Leukocyte Test a good predictor of Clostridium difficile associated diarrhea?. Ann Clin Microbiol Antimicrob 2006, 5:9.
14. Stevens V., Dumyati G., Fine L.S., Fisher S.G., van Wijngaarden E. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis 2011, 53(1):42-48.
15. Manges A.R., Labbe A., Loo V.G., Atherton J.K., Behr M.A., Masson L., et al. Comparative metagenomic study of alterations to the intestinal microbiota and risk of nosocomial Clostridum difficile-associated disease. J Infect Dis 2010, 202(12):1877-1884.
16. Eyre D.W., Cule M.L., Wilson D.J., Griffiths D., Vaughan A., O'Connor L., et al. Diverse sources of C. difficile infection identified on whole-genome sequencing. N Engl J Med 2013, 369(September (13)):1195-1205.
17. Aldeyab M.A., Kearney M.P., Scott M.G., Aldiab M.A., Alahmadi Y.M., Darwish Elhajji F.W., et al. An evaluation of the impact of antibiotic stewardship on reducing the use of high-risk antibiotics and its effect on the incidence of Clostridium difficile infection in hospital settings. J Antimicrob Chemother 2012, 67(12):2988-2996.
18. Dancer S.J., Kirkpatrick P., Corcoran D.S., Christison F., Farmer D., Robertson C. Approaching zero: temporal effects of a restrictive antibiotic policy on hospital-acquired Clostridium difficile, extended-spectrum β-lactamase-producing coliforms and meticillin-resistant Staphylococcus aureus. Int J Antimicrob Agents 2013, 41(2):137-142.
19. Dial S., Delaney J.A., Barkun A.N., Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005, 294:2989-2995.
20. Cunningham R., Dale B., Undy B., Gaunt N. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhea. J Hosp Infect 2003, 54:243-245.
21. Dial S., Alrasadi K., Manoukian C., Huang A., Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004, 171:33-38.
22. Shah S., Lewis A., Leopold D., Dunstan F., Woodhouse K. Gastric acid suppression does not promote clostidrial diarrhea in the elderly. QJM 2000, 93:175-181.
23. Aichinger E., Schleck C.D., Harmsen W.S., Nyre L.M., Patel R. Nonutility of repeat laboratory testing for detection of Clostridium difficile by use of PCR or enzyme immunoassay. J Clin Microbiol 2008, 46:3795-3797.
24. Debast S.B., Bauer M.P., Kuijper E.J., European Society of Clinical Microbiology and Infectious Diseases European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 2014, 20(March (Suppl. 2)):1-26.